What AlveoGene does

AlveoGene is a privately held, Oxford-based biotech founded in 2023 that develops inhaled gene therapies for rare respiratory diseases using its proprietary InGenuiTy™ lentiviral delivery platform. The platform is a next-generation pseudotyped lentiviral vector (rSIV.F/HN) licensed exclusively from the UK Respiratory Gene Therapy Consortium, capable of direct lung delivery via nebulizer (for older patients) or endotracheal instillation (for neonates), with high payload capacity (~3x AAV), repeat dosing without loss of efficacy, and 80% shared CMC backbone across candidates. Its four-asset pipeline targets alpha-1 antitrypsin deficiency lung disease (AVG-001, pre-clinical), neonatal surfactant protein B deficiency (AVG-002, candidate selection with FDA Orphan Drug and Rare Pediatric Disease Designations), ABCA3 surfactant deficiency (AVG-003, candidate selection), and idiopathic pulmonary fibrosis (AVG-004, discovery).

The company operates a pre-clinical, pre-revenue business model with revenue expected to derive from commercialization of approved gene therapy products in rare respiratory indications and from the potential sale of contingent Priority Review Vouchers tied to FDA designations on AVG-002 (and potentially AVG-003). Its target patient populations are highly fragmented — neonates with fatal surfactant deficiencies (SP-B affects ~1 in 1M newborns; ABCA3 is 3–5x more common) and AATD lung disease patients (100,000+ in the US and a similar number in Europe). The platform has been independently validated through Boehringer Ingelheim's Phase 1 Lenticlair trial in cystic fibrosis, which commenced in December 2024.

AlveoGene is venture-backed by Oxford Science Enterprises, Harrington Discovery Institute, and Old College Capital (University of Edinburgh's venture fund), with six co-founders from the UK Respiratory Gene Therapy Consortium providing scientific leadership and Executive Chair David Hipkiss (formerly of Prosonix, acquired for £100M) leading corporate development. As of late 2025 the company is raising a Series A to advance its pipeline, and management is leveraging industry conferences (ATS, BioTrinity, JPM Week 2026) for investor outreach.

Name

AlveoGene

Legal name

AlveoGene

Website

https://alveogene.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

AlveoGene is a privately held Oxford-based biotech developing inhaled gene therapies for rare respiratory diseases using its proprietary InGenuiTy lentiviral delivery platform, with a four-asset pipeline targeting AATD lung disease, neonatal surfactant protein deficiencies, and idiopathic pulmonary fibrosis.

Ownership category

akta.pro rank

Product category

Inhaled Gene Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)

akta.pro secondary industries

Alpha-1 Antitrypsin (AAT) Therapies (HLAIAHAD), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

Keywords

• Inhaled gene therapy
• Lentiviral delivery platform
• Rare respiratory diseases
• Orphan drug development
• Respiratory biotherapeutics

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Gene Therapy Product Sales: AlveoGene is developing a pipeline of inhaled gene therapy products for rare respiratory diseases (AVG-001 for AATD, AVG-002 for SP-B deficiency, AVG-003 for ABCA3 deficiency, AVG-004 for IPF). The company plans to commercialize these products upon regulatory approval, targeting the rare disease market with significant unmet need and premium pricing potential.
2. Priority Review Voucher: AVG-002 has received Rare Pediatric Disease Designation and Orphan Drug Designation from FDA, qualifying the company for a Priority Review Voucher upon marketing authorisation. These vouchers have recently sold for $100-200 million each.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

AlveoGene develops inhaled gene therapies for rare respiratory diseases using its proprietary InGenuiTy™ lentiviral delivery platform (rSIV.F/HN pseudotyped vector), which enables direct lung delivery via nebulizer or instillation. The company is advancing a pipeline of four gene therapy candidates (AVG-001 for AATD, AVG-002 for SP-B deficiency, AVG-003 for ABCA3 deficiency, AVG-004 for IPF) and licenses the platform for indications outside its core focus (CFTR rights licensed to Boehringer Ingelheim).

Product overview

AlveoGene is a lung-targeted inhaled gene therapy company advancing a pipeline of novel inhaled gene therapies for rare respiratory diseases based on its proprietary InGenuiTy lentiviral platform. The platform enables delivery of gene therapies directly to lung tissues via nebulizer (for children, teenagers, adults) or direct instillation (for neonates). The product pipeline includes four candidates: AVG-001 (pre-clinical) for Alpha-1 Antitrypsin Deficiency lung disease, AVG-002 (candidate selection) for Surfactant Protein B deficiency (with FDA Orphan Drug Designation and Rare Pediatric Disease Designation), AVG-003 (candidate selection) for ABCA3 surfactant protein deficiency, and AVG-004 (discovery) for Idiopathic Pulmonary Fibrosis.

Differentiator

Problem solved

Functional benefit

Products and services

• AVG-001 Novel inhaled gene therapy candidate for Alpha-1 Antitrypsin Deficiency (AATD) Lung Disease. Uses AlveoGene's proprietary lentiviral vector to deliver a transgene to the lung, promoting long-term localised production of alpha-1 antitrypsin protein. Currently at pre-clinical stage.
• AVG-002 Inhaled gene therapy candidate for Surfactant Protein B (SP-B) Deficiency, a lethal neonatal condition. Uses AlveoGene's proprietary lentiviral vector to deliver a functional SP-B gene to the lung alveolar region. Received FDA Orphan Drug Designation (December 2024) and Rare Pediatric Disease Designation (November 2024). Currently at candidate selection stage.
• AVG-003 Inhaled gene therapy candidate for ABCA3 Surfactant Protein Deficiency, an autosomal recessive condition affecting newborns and children. Uses the same proprietary lentiviral vector backbone as other AlveoGene candidates. Expected to seek FDA Rare Pediatric Disease Designation and Orphan Drug Status in 2025/2026. Currently at candidate selection stage.
• AVG-004 Inhaled gene therapy candidate for Idiopathic Pulmonary Fibrosis (IPF). Consists of two or more transgenes packaged in AlveoGene's proprietary lentiviral vector backbone delivered simultaneously to the lung. Currently at discovery stage, with candidate selection expected in 2025.
• InGenuiTy™ Lentiviral Delivery Platform Proprietary next-generation lentiviral delivery platform (rSIV.F/HN pseudotyped lentiviral vector) designed for respiratory gene therapy. Licensed from the UK Respiratory Gene Therapy Consortium (CFTR gene licensed to Boehringer Ingelheim; all other respiratory indications exclusively held by AlveoGene). IP estate covers more than 10 patent families with protection through 2042.

Quantifiable outcome

• AVG-002 single dose extends survival substantially longer in SP-B knockout murine models vs other candidates in development
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• UK Respiratory Gene Therapy Consortium (GTC)coreStrategic or Co-development Partner · 14 September 2023Six leading scientists from the UK Respiratory Gene Therapy Consortium (GTC) serve as co-founders of AlveoGene. The GTC was founded in 2001 at Imperial College London and Universities of Oxford and Edinburgh, with 20+ years of experience in respiratory gene therapy. AlveoGene has exclusive license to the InGenuiTy™ platform developed by GTC (excluding CFTR gene for cystic fibrosis).
• Boehringer IngelheimcoreTechnology or Integration · 14 September 2023Boehringer Ingelheim has licensed the InGenuiTy™ platform (for CFTR gene) and commenced Phase 1 clinical trial (Lenticlair) in Cystic Fibrosis in December 2024. This validates the InGenuiTy platform technology and demonstrates scalable GMP manufacturing capability. AlveoGene has exclusive rights for the platform in all other respiratory indications excluding CF.
• Oxford-Harrington Rare Disease Centre's Therapeutics AcceleratorcoreStrategic or Co-development Partner · 14 September 2023AlveoGene is the first company being advanced under the Oxford-Harrington Rare Disease Centre's Therapeutics Accelerator, combining Oxford Science Enterprises and Harrington Discovery Institute resources for rare disease therapeutics development.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• ReCode Therapeutics: Pre-clinical/early-clinical biotech developing inhaled mRNA-based gene therapy for cystic fibrosis and primary ciliary dyskinesia via lipid nanoparticle delivery. Closest direct comparable as another respiratory-focused gene therapy company targeting rare pulmonary diseases with novel delivery platforms.
• Insmed: Commercial-stage pulmonary disease company with Arikayce (inhaled liposomal amikacin) for MAC lung infection and a pipeline including brensocatib for bronchiectasis; direct competitor for AATD lung disease patients and inhaled orphan pulmonary therapeutics.
• Boehringer Ingelheim: Licensed the InGenuiTy lentiviral platform from AlveoGene for the CFTR gene and commenced a Phase 1 trial (Lenticlair) in cystic fibrosis in December 2024, using the same vector backbone and giving them a direct stake in the platform's clinical validation.
• Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with pulmonary programs in development (e.g., AATD lung via inhaled RNAi); directly comparable as a developer of inhaled nucleic acid-based therapeutics targeting the same AATD lung disease indication.

Broad incumbents

• Krystal Biotech: Commercial-stage gene therapy company (Vyjuvek for dystrophic EB) using a different vector platform (HSV-1) for rare diseases; comparable as a fully integrated rare-disease genetic medicine company that has navigated from platform through FDA approval.
• Vertex Pharmaceuticals: Dominant respiratory therapeutics company with the CF franchise (Trikafta/Kaftrio) and a major gene therapy collaboration with CRISPR Therapeutics (Casgevy); comparable as a deep-pocketed respiratory player with active gene therapy ambitions.
• uniQure: Commercial-stage gene therapy company (Hemgenix approved for hemophilia B) using AAV vectors; comparable as a gene therapy company navigating commercial-scale manufacturing, regulatory milestones, and rare disease economics.
• PTC Therapeutics: Mid-cap rare disease therapeutics company with portfolio spanning genetic disorders and pulmonology, including gene therapy programs; comparable as an established rare-disease commercial-stage player relevant to AlveoGene's go-to-market ambitions.

Emerging players

• Entrada Therapeutics: Clinical-stage biotech developing intracellular delivery approaches (cyclic peptide-conjugated oligonucleotides) for neuromuscular diseases; comparable as a platform-stage rare disease company with novel delivery technology and similar pre-revenue profile.
• CRISPR Therapeutics: Commercial-stage gene editing company (Casgevy, partnered with Vertex) with active programs in respiratory genetic diseases; comparable as a frontier genetic medicine company targeting pulmonary monogenic diseases with curative intent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AlveoGene